HLA class-I-peptide stability mediates CD8+ T cell immunodominance hierarchies and facilitates HLA-associated immune control of HIV

Clarety Kaseke; Ryan J. Park; Nishant K. Singh; Dylan Koundakjian; Arman Bashirova; Wilfredo F. Garcia Beltran; Overbeck C. Takou Mbah; Jiaqi Ma; Fernando Senjobe; Jonathan M. Urbach; Anusha Nathan; Elizabeth J. Rossin; Rhoda Tano-Menka; Ashok Khatri; Alicja Piechocka-Trocha; Michael T. Waring; Michael E. Birnbaum; Brian M. Baker; Mary Carrington; Bruce D. Walker; Gaurav D. Gaiha

Cell Reports (Jul 2021)

HLA class-I-peptide stability mediates CD8+ T cell immunodominance hierarchies and facilitates HLA-associated immune control of HIV

Clarety Kaseke,
Ryan J. Park,
Nishant K. Singh,
Dylan Koundakjian,
Arman Bashirova,
Wilfredo F. Garcia Beltran,
Overbeck C. Takou Mbah,
Jiaqi Ma,
Fernando Senjobe,
Jonathan M. Urbach,
Anusha Nathan,
Elizabeth J. Rossin,
Rhoda Tano-Menka,
Ashok Khatri,
Alicja Piechocka-Trocha,
Michael T. Waring,
Michael E. Birnbaum,
Brian M. Baker,
Mary Carrington,
Bruce D. Walker,
Gaurav D. Gaiha

Affiliations

Clarety Kaseke: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
Ryan J. Park: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Harvard Radiation Oncology Program, Boston, MA 02114, USA
Nishant K. Singh: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
Dylan Koundakjian: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
Arman Bashirova: Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
Wilfredo F. Garcia Beltran: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
Overbeck C. Takou Mbah: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
Jiaqi Ma: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46556, USA
Fernando Senjobe: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Program in Virology, Harvard Medical School, Boston, MA 02114, USA
Jonathan M. Urbach: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
Anusha Nathan: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
Elizabeth J. Rossin: Department of Ophthalmology, Massachusetts Eye and Ear, Boston, MA 02114, USA; The Broad Institute, Cambridge, MA 02142, USA
Rhoda Tano-Menka: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
Ashok Khatri: Massachusetts General Hospital Endocrine Unit and Department of Medicine, Harvard Medical School, Boston, MA 02114, USA
Alicja Piechocka-Trocha: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
Michael T. Waring: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
Michael E. Birnbaum: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 02142, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Brian M. Baker: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA; Harper Cancer Research Institute, University of Notre Dame, South Bend, IN 46556, USA
Mary Carrington: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA
Bruce D. Walker: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; The Broad Institute, Cambridge, MA 02142, USA; Center for the AIDS Programme of Research in South Africa, Durban 4001, South Africa; Institute for Medical Engineering and Science and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Gaurav D. Gaiha: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA 02114, USA; Corresponding author

Journal volume & issue: Vol. 36, no. 2
p. 109378

Abstract

Read online

Summary: Defining factors that govern CD8+ T cell immunodominance is critical for the rational design of vaccines for viral pathogens. Here, we assess the contribution of human leukocyte antigen (HLA) class-I-peptide stability for 186 optimal HIV epitopes across 18 HLA alleles using transporter associated with antigen processing (TAP)-deficient mono-allelic HLA-expressing cell lines. We find that immunodominant HIV epitopes increase surface stabilization of HLA class-I molecules in comparison to subdominant epitopes. HLA class-I-peptide stability is also strongly correlated with overall immunodominance hierarchies, particularly for epitopes from high-abundance proteins (e.g., Gag). Moreover, HLA alleles associated with HIV protection are preferentially stabilized by epitopes derived from topologically important viral regions at a greater frequency than neutral and risk alleles. These findings indicate that relative stabilization of HLA class-I is a key factor for CD8+ T cell epitope immunodominance hierarchies, with implications for HIV control and the design of T-cell-based vaccines.

Published in Cell Reports

ISSN: 2211-1247 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Science: Biology (General)
Website: http://www.cell.com/cell-reports/home

About the journal

Abstract

Keywords